Fennec Pharmaceuticals Inc.
https://fennecpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Fennec Pharmaceuticals Inc.
Bayer Heralds Potential Of BlueRock Parkinson's Stem Cell Therapy
Bayer pharma research head Christian Rommel has told Scrip he was excited about the Phase I data on Parkinson's disease prospect bemdaneprocel, which is comprised of dopamine-producing neurons derived from pluripotent stem cells, but also advocated caution at this early stage.
Deal Watch: Novartis, Ionis Team Up Again In Cardiovascular Disease
Plus deals involving ProQR/ Thea, Aeglea/Immedica, Ayala/Biolight, Quince/EryDel, ImmunoBiochem/ImmunoGen and GSK/LimmaTech, as well as deals in brief.
Chinese ADC, RNA Therapy Developers Lead May/June Fundraising
Emerging companies including Bliss Biopharmaceutical, Coherent Biopharma and WestGene Biopharma lifted China biotech funding from May to mid-June.
FTC Rebukes Supernus Efforts To Block Sales Of Injector Pen For Use With Generic Apokyn
Agency refutes Supernus’ defense that Sage’s generic drug cartridges are ‘free-riding’ on the supply of the injector pen for its branded product. Company’s alleged exclusionary contract with pen distributor and pressure on specialty pharmacies not to provide the generic involve important antitrust issues, FTC tells court.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Adherex Technologies Inc.
- Cadherin Biomedical, Inc.
- Fennec Pharmaceuticals (EU) Limited
- Oxiquant, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice